A dietary tomato supplement prevents prostate cancer in TRAMP mice

Cancer Prevention Research

Volumn 3, Issue 10, 2010, Pages 1284-1291

  Pannellini, Tania ^a   Iezzi, Manuela ^a   Liberatore, Marcella ^a   Sabatini, Federica ^a   Iacobelli, Stefano ^a   Rossi, Cosmo ^a   Alberti, Saverio ^a   Di Ilio, Carmine ^a   Vitaglione, Paola ^b   Fogliano, Vincenzo ^b   Piantelli, Mauro ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; DIET SUPPLEMENTATION; FEMALE; INFLAMMATION; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TOMATO;

ADENOCARCINOMA; ANIMALS; ANTIOXIDANTS; DIET; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; LYCOPERSICON ESCULENTUM; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHYTOTHERAPY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958525475     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0237     Document Type: Article

References (47)

1. Jema A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007;16:2193-203.
3. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27:2712-25.
4. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004;13:340-5.
5. Wu K, Erdman JW, Jr., Schwartz SJ, et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2004;13:260-9.
6. Gupta S. Prostate cancer chemoprevention: current status and future prospects. Toxicol Appl Pharmacol 2007;224:369-76.
7. Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007;99:1074-85.
8. Matos HR, Capelozzi VL, Gomes OF, Mascio PD, Medeiros MH. Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate. Arch Biochem Biophys 2001;396:171-7.
9. Nahum A, Hirsch K, Danilenko M, et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 2001;20:3428-36.
10. Herzog A, Siler U, Spitzer V, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005;19:272-4.
11. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001;93: 1872-9.
12. Kucuk O, Sarkar FH, Djuric Z, et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 2002;227:881-5.
13. Imaida K, Tamano S, Kato K, et al. Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 2001;22:467-72.
14. Mossine VV, Chopra P, Mawhinney TP. Interaction of tomato lycopene and ketosamine against rat prostate tumorigenesis. Cancer Res 2008;68:4384-91.
15. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW, Jr., Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone- treated rats fed tomato powder, lycopene, or energy-restricted diets. J Nat Cancer Inst 2003;95:1578-86.
16. Canene-Adams K, Lindshield BL, Wang S, et al. Combinations of tomato and broccoli enhance antitumor activity in Dunning R3327-H prostate adenocarcinomas. Cancer Res 2007;67:836-43.
17. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
18. Huss WJ, Gray DR, Tavakoli K, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007;9:938-50. (Pubitemid 350086439)
19. Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46. (Pubitemid 351186384)
20. Bono AV, Montironi R, Pannellini T, et al. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice. Prostate Cancer Prostatic Dis 2008; 11:377-83.
21. Vitaglione P, Fogliano V, Stingo S, Scalfi L, Caporaso N, Morisco F. Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. Eur J Clin Nutr 2007;61:906-15. (Pubitemid 47040315)
22. Esposito E, Capasso M, di Tomasso N, et al. Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis. Brain Res 2007;1168:90-6. (Pubitemid 47334814)
23. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996;239:70-6.
24. Cohen LA. A review of animal model studies of tomato carotenoids, lycopene, and cancer chemoprevention. Exp Biol Med (Maywood) 2002;227:864-8.
25. Siler U, Barella L, Spitzer V, et al. Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 2004;18:1019-21. (Pubitemid 39561511)
26. Barve A, Khor TO, Nair S, et al. γ-Tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 2009;124:1693-9.
27. dos Anjos Ferreira AL, Yeum KJ, Russell RM, Krinsky NI, Tang G. Enzymatic and oxidative metabolites of lycopene. J Nutr Biochem 2004;15:493-502.
28. Erdman JW, Jr., Ford NA, Lindshield BL. Are the health attributes of lycopene related to its antioxidant function? Arch Biochem Biophys 2009;483:229-35.
29. Chaiswing L, Zhong W, Cullen JJ, Oberley LW, Oberley TD. Extracellular redox state regulates features associated with prostate cancer cell invasion. Cancer Res 2008;68:5820-6.
30. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
31. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol 2006;3:157-69.
32. Maitland NJ, Collins AT. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? J Cell Biochem 2008;105:931-9.
33. Adhami VM, Siddiqui IA, Sarfaraz S, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009;15:1947-53.
34. Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology 2006;68:244-8. (Pubitemid 44175509)
35. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
36. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 2007;67:5789-97. (Pubitemid 46985012)
37. Moore BB, Arenberg DA, Stoy K, et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999;154: 1503-12. (Pubitemid 29226445)
38. Shen H, Lentsch AB. Progressive dysregulation of transcription factors NF-κB and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 2004;286: C840-7.
39. Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006;16:831-6.
40. Dalgleish AG, O'Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 2002; 84:231-76.
41. Duoe D, Krawczenko A, Załecki P, et al. IL-7 receptor is present on human microvascular endothelial cells. Immunol Lett 2003;86:163-8.
42. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497-505.
43. Furuya Y, Nishio R, Junicho A, Nagakawa O, Fuse H. Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer. Int Urol Nephrol 2005;37:69-71. (Pubitemid 41236246)
44. Wallner L, Dai J, Escara-Wilke J, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgenindependent phenotype in orchiectomized mice. Cancer Res 2006; 66:3087-95.
45. Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007;69:113-7.
46. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis - new insights into epithelial-stromal interactions. Cancer Cell 2007; 12:495-7.
47. Canene-Adams K, Campbell JK, Zaripheh S, Jeffery EH, Erdman JW, Jr. The tomato as a functional food. J Nutr 2005;135:1226-30.